Latest news with #CNBCDisruptor50
Yahoo
4 days ago
- Business
- Yahoo
Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the addition of healthcare veteran Elizabeth Bierbower to its Board of Directors. "As we continue to round out our board's experience, Elizabeth's extensive leadership with some of the largest health plans and deep financial expertise will be invaluable as we scale and innovate across the women's health and family building spectrum," said Pete Anevski, CEO of Progyny. "Her insights will support our strategy to deliver even more value to our members, clients, and shareholders as we expand our reach and impact." Bierbower brings more than 30 years of experience in the healthcare industry, having held leadership roles across health plans, provider services, and care innovation. She most recently served as Chairman and CEO of Friday Health Plans and held various senior positions at Humana, including Segment President, President of the Employer Group Segment, and Chief Operating Officer of the Specialty Benefits division. Prior to Humana, she held leadership roles at Highmark Blue Cross Blue Shield and Coventry Health Care. Bierbower's depth of healthcare experience also includes serving on the board of directors of numerous companies including Option Care Health, the largest national independent provider for infusion therapy, as well as the boards of several privately held companies, including BlueSprig, Quest Analytics, Paradigm Corp., and Point32Health. 'Progyny is setting the standard for what comprehensive, outcomes-based women's health and family building benefits should look like in today's workforce,' said Bierbower. 'I'm joining the board at an exciting time as the company continues its expansion of both products and reach, and I look forward to contributing to the team's objective of advancing access to high-quality care for women and families.' For more information about Progyny and its Board of Directors, please visit About ProgynyProgyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact: Investors:James Hartinvestors@ Media:Alexis Fordmedia@ in to access your portfolio
CNBC
19-05-2025
- Business
- CNBC
Regeneron Pharmaceuticals to buy 23andMe for $256 million, including data
Regeneron Pharmaceuticals on Monday announced it will acquire "substantially all" of 23andMe's assets for $256 million. The drugmaker participated in a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for for Chapter 11 bankruptcy protection in March. Regeneron is buying 23andMe's Personal Genome Service, Total Health and Research Services business lines, according to a release. "We believe we can help 23andMe deliver and build upon its mission to help people learn about their own DNA and how to improve their personal health, while furthering Regeneron's efforts to improve the health and wellness of many," Dr. George Yancopoulos, Regeneron's president, said in a statement. Regeneron will not buy the company's telehealth subsidiary, Lemonaid Health, which 23andMe had acquired for around $400 million in 2021. Lemonaid Health will be shut down, but Regeneron has offered to employ all staffers of the acquired business units, according to the release. The deal is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri. Pending approval, it's expected to close in the third quarter of this year, according to the release. 23andMe rocketed into the mainstream because of its at-home DNA testing kits that gave customers insight into their family histories and genetic profiles. The five-time CNBC Disruptor 50 company went public in 2021 via a merger with a special purpose acquisition company. At its peak, 23andMe was valued at around $6 billion. The company struggled to generate recurring revenue and stand up viable research and therapeutics businesses after going public, and it's been plagued by privacy concerns since hackers accessed the information of nearly 7 million customers in 2023. In its bankruptcy proceedings, 23andMe required all bidders to comply with its privacy policies, and a court-appointed, independent "Consumer Privacy Ombudsman" will assess the deal, the companies said. Several lawmakers and officials, including the Federal Trade Commission, had expressed concerns about the safety of consumers' genetic data through 23andMe's sale process. The privacy ombudsman will present a report on the acquisition to the court by June 10. "We are pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice and consent with respect to their genetic data," Mark Jensen, 23andMe's board chair, said in a statement.
Yahoo
12-05-2025
- Business
- Yahoo
Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact:Investors:James Hartinvestors@ Media:Alexis Fordmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact:Investors:James Hartinvestors@ Media:Alexis Fordmedia@
Yahoo
24-03-2025
- Business
- Yahoo
23andMe's journey from DNA testing pioneer to bankruptcy
(Reuters) - 23andMe filed for bankruptcy on Sunday, hit by faltering demand for its ancestry testing kits as it struggled to contain the reputational damage from a widespread data breach. Presented below is a sequence of events outlining the journey of the San Francisco-based firm, once considered a pioneer in the DNA-testing space: 2006: Anne Wojcicki, Linda Avey and Paul Cusenza come together as co-founders of 23andMe. A year later, the company launches its first direct-to-consumer genetic testing kit, which provides more than 200 health and trait reports as well as genetic ancestry information. 2008: Time magazine labels 23andMe's saliva-based genetic testing kit the "Invention of the Year." 2013: The U.S. Food and Drug Administration issues a warning letter to 23andMe to stop selling its genetic tests due to concerns that it failed to provide any indication that it had analytically or clinically validated the test kits for its intended uses. 2015: After two years of working with regulators — including meeting some of the FDA's reporting requirements — the company is able to market its DNA test kit directly to individuals in the United States. 2016: 23andMe makes it to the CNBC Disruptor 50 list of companies. 2017: Oprah Winfrey names the 23andMe genetic testing kit one of her "favorite things" of the year. 2018: 23andMe signs a four-year collaboration agreement with British drugmaker GSK, focusing on research and development of new medicines using human genetics. 2019: American singer Lizzo dresses up as the company's DNA test kit for Halloween, and 23andMe is featured in actor Eddie Murphy's sketch on Saturday Night Live. Several media outlets report that the company is seeing an almost 54% decline in sales of its genetic testing kits. 2021: 23andMe goes public after merging with billionaire Richard Branson's SPAC, notching up a $3.5 billion valuation. Its market capitalization nears $6 billion later that year and the company spends $400 million to buy telehealth firm Lemonaid Health. 2023: 23andMe notifies customers of a data breach in its "DNA Relatives" feature that allowed them to compare ancestry information with users worldwide. It is later revealed that hackers stole ancestry data on 6.9 million users. April 2024: Co-founder and CEO Anne Wojcicki considers making an offer to take the company private. July 2024: Wojcicki makes her first non-binding proposal to acquire all of the company's outstanding shares for 40 cents per share. August 2024: 23andMe's board rejects Wojcicki's take-private offer, calling it "insufficient." Lemonaid Health begins to offer branded and compounded versions of Novo Nordisk's popular weight-loss drug Wegovy. September 2024: 23andMe agrees to pay $30 million to settle a lawsuit related to the data breach. Nearly all of the independent directors resign from the company's board after not receiving a satisfactory offer from CEO Wojcicki. November 2024: The firm cuts about 40%, or 200 employees, from its workforce and discontinues the development of all its therapies as part of a restructuring program. 23andMe also commences a strategic alternatives process for all in-house therapeutic programs. January 2025: 23andMe reports total revenue of $60.3 million in the third quarter of its fiscal year 2025, including $19.3 million from non-recurring research services under its deal with GSK. As of December 31, 2024, the company reports cash and cash equivalents of $79.4 million. March 2025: A special committee of 23andMe's board unanimously rejects CEO Wojcicki's latest proposal to buy the company for 41 cents per share. The firm files for bankruptcy later in the month, and Wojcicki resigns as CEO to participate as an independent bidder during the bankruptcy process.
